Fax: (011) 81-463-937134
Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma†
Comparison with surgical resection
Article first published online: 11 MAY 2010
Copyright © 2010 American Cancer Society
Volume 116, Issue 15, pages 3638–3644, 1 August 2010
How to Cite
Kagawa, T., Koizumi, J., Kojima, S.-i., Nagata, N., Numata, M., Watanabe, N., Watanabe, T. and Mine, T. (2010), Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma. Cancer, 116: 3638–3644. doi: 10.1002/cncr.25142
The Tokai RFA Study Group consists of Shoichi Dowaki, MD Kosuke Tobita, MD Toshihide Imaizumi, MD (Department of Surgery, Tokai University Hospital), Koichi Shiraishi, MD (Department of Gastroenterology, Tokai University Hachioji Hospital), Shinji Takashimizu, MD (Department of Gastroenterology, Tokai University Oiso Hospital), Yasuo Ohtani, MD (Department of Surgery, Tokai University Oiso Hospital), and Yoshiro Iwata, MD (Department of Radiology, Tokai University Oiso Hospital).
- Issue published online: 20 JUL 2010
- Article first published online: 11 MAY 2010
- Manuscript Accepted: 9 NOV 2009
- Manuscript Revised: 20 OCT 2009
- Manuscript Received: 31 AUG 2009
- hepatocellular carcinoma;
- radiofrequency ablation;
- transcatheter arterial chemoembolization
Radiofrequency ablation (RFA) is becoming a well-known local therapy for hepatocellular carcinoma (HCC). Transcatheter arterial chemoembolization (TACE) is expected to enhance the effects of subsequent RFA by reducing arterial blood flow. However, the long-term efficacy of this combined therapy has not been elucidated. In this study, the survival rates of patients who received TACE combined with RFA (TACE + RFA) were compared with those of patients treated surgically.
The study included consecutive patients who received TACE + RFA or surgical resection as the initial curative treatment for HCC between 2000 and 2005 at Tokai University Hospital. Inclusion criteria were a single HCC ≤50 mm or up to 3 HCCs ≤30 mm, presence of cirrhosis classified as Child-Pugh class A, no vascular invasion, and no extrahepatic metastasis.
Sixty-two patients (23 women, 39 men; aged 67.5 ± 8.4 years [mean ± standard deviation]) received TACE + RFA, and 55 patients (15 women, 40 men; aged 66.1 ± 8.4 years) underwent surgical resection. Median follow-up periods were similar (50 months in the TACE + RFA group vs 49 months in the resection group). The probabilities of overall survival at 1, 3, and 5 years in the TACE + RFA group (100%, 94.8%, and 64.6%, respectively) were similar (P = .788) to those in the resection group (92.5%, 82.7%, and 76.9%, respectively). Two major RFA-related complications were observed (1.5%).
RFA combined with TACE is an efficient and safe treatment that provides overall survival rates similar to those achieved with surgical resection. Cancer 2010. © 2010 American Cancer Society.